|
Monday, February 9, 2009
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
DiaLean
Therapeutic Developers
About
|
DiaLean's mission is to develop therapeutics for weight management and hormonal imbalance based on proprietary proteins DiaLean discovers using a proprietary bioinformatics methodology.
DiaLean's major goal in the next 3 years will be to advance Dln-101, its lead compound, successfully through phase 1 and phase 2 clinical trials. Dln-101 is a naturally occurring splice variant of ghrelin. It is a 24 amino acid peptide that can be easily manufactured in large quantities at relatively low cost. The compound is targeted at the multi-billion dollar cancer cachexia market. Cancer related cachexia is physical wasting with significant loss of weight and muscle mass that many cancer patients undergo. Unlike ghrelin which induces mostly fat body mass, efficacy studies have shown that Dln-101 induces mostly lean body mass making it a much more effective candidate for treating cancer related cachexia. There are currently no approved drugs to treat cancer related cachexia.
The secondary goals of DiaLean are to advance one or more of the peptides and proteins it discovered through phase 1, for example:
- Dln-201, a novel splice variant of ghrelin targeted at the diabetes and obesity market.
- Dln-301, a GLP-1 splice variant, targeted at the diabetes type II market.
- Dln-401, a novel splice of the pancreatic polypeptide protein, targeted at the obesity market
- Dln-701, a novel splice variant of adiponectin, targeted at the diabetes market
DiaLean will also demonstrate the efficacy of its additional proprietary molecules which include a novel splice variant of insulin. Funding for the preclinical and clinical development of these candidates will be obtained through partnerships and licensing agreements.
3 Major Issues
|
-
In the current status of the economy what can we do to get funded and who should we approach?
-
Our drug is targeted at the cancer cachexia market but can be used in any type of cachexia (COPD, CHF, ESRD, AIDS etc.). Is cancer cachexia the best choice?
-
We have many molecules in our pipeline. What are the requirements for licensing to big pharma today??
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Liat Mintz and Eli Mintz, founders of DiaLean will deliver the Company's "Elevator" Pitch to the Group
8:15 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
DiaLean Webcast 02/10/09
|
|
Al Giovenella
Alan Goldberg
Bill Moore
Boas Gonen
Bob Smith
Brenda Gavin
Chana Bursztyn
Dale Hartupee
Daniel McCallus
Don Skerrett
Glenn Hughes
Jeff Martini
Jim Johnson
Joe Johnson
Joe Patterson
Joe Zindulis
Johanna Allston
Kevin Brown
Marvin Siegel
Michael Schina
Paula Goldberg
Peter van der Kam
Ralph Earl
Tom Thompson
Tracy Shickel
Wayne Barz
William Kinney
|
